ARCHIVES

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

Firm Buys Rights To NKT Cells From Beth Israel Deaconess.

July 28, 2000

NCI Cooperative Group, Cancer Center Trials Listed

June 27, 2008

Cancer Prevention: NSABP Publishes P-1 Data, Finds Risk Of Breast Cancer Cut By 49 Percent

September 18, 1998

NCI Launches M-PACT Next-Generation Trial As Group System Nears March 1 Transition

February 21, 2014

In Brief: ACCC to Bid On Ovarian Cancer Treatment RFP; Community MDs Handle 90% Of Ovarian Patients

September 5, 1975

Xeloda + Oxaliplatin Compares To FOLFOX-4 In First Line

January 30, 2009